BioCis Pharma Initiates Phase IIa Atopic Dermatitis Trial
BioCis Pharma, a privately-held drug development company, has initiated Phase IIa clinical testing of ProtoCure emulsion cream, the company’s novel topical drug for dermatology.
The double-blind, vehicle-controlled study is designed to evaluate the tolerability and efficacy of the topical product in a total of 18 subjects with mild to moderate forms of atopic dermatitis. The subjects will apply ProtoCure emulsion cream up to four weeks to the skin areas affected by the disease.
Lasse Leino, CEO of BioCis Pharma, said: “Building on the results from our earlier Phase I dermatology studies demonstrating excellent safety, we are pleased to begin this important Phase II study in subjects with atopic dermatitis.
“This study will allow us to assess efficacy of ProtoCure emulsion cream in chronic skin inflammation. We have already shown in the earlier Phase I study that our product has positive effects in acute skin irritation.”